Document Detail


The role of apoptosis in LDL transport through cultured endothelial cell monolayers.
MedLine Citation:
PMID:  19709659     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have previously shown that leaky junctions associated with dying or dividing cells are the dominant pathway for low density lipoprotein (LDL) transport under convective conditions, accounting for more than 90% of the transport [Cancel LM, Fitting A, Tarbell JM. In vitro study of LDL transport under pressurized (convective) conditions. Am J Physiol Heart Circ Physiol 2007;293:H126-32]. To explore the role of apoptosis in the leaky junction pathway, TNFalpha and cycloheximide (TNFalpha/CHX) were used to induce an elevated rate of apoptosis in cultured bovine aortic endothelial cell (BAEC) monolayers and the convective fluxes of LDL and water were measured. Treatment with TNFalpha/CHX induced a 18.3-fold increase in apoptosis and a 4.4-fold increase in LDL permeability. Increases in apoptosis and permeability were attenuated by treatment with the caspase inhibitor Z-VAD-FMK. Water flux increased by 2.7-fold after treatment with TNFalpha/CHX, and this increase was not attenuated by treatment with Z-VAD-FMK. Immunostaining of the tight junction protein ZO-1 showed that TNFalpha/CHX treatment disrupts the tight junction in addition to inducing apoptosis. This disruption is present even when Z-VAD-FMK is used to inhibit apoptosis, and likely accounts for the increase in water flux. We found a strong correlation between the rate of apoptosis and the permeability of BAEC monolayers to LDL. These results demonstrate the potential of manipulating endothelial monolayer permeability by altering the rate of apoptosis pharmacollogicaly. This has implications for the treatment of atherosclerosis.
Authors:
Limary M Cancel; John M Tarbell
Related Documents :
10946219 - Immunological responses to oxidized ldl.
1436109 - Rat liver protein linking chemical and immunological detoxification systems.
17395779 - Bovine apolipoprotein b-100 is a dominant immunogen in therapeutic cell populations cul...
17621699 - The role of macrophage migration inhibitory factor in maintaining the immune privilege ...
10964909 - Macrophage colony-stimulating factor rapidly enhances beta-migrating very low density l...
11425039 - Granulocyte/macrophage colony-stimulating factor plays an essential role in oxidized lo...
21410709 - Contrasting growth and adaptive responses of two oak species to flooding stress: role o...
16987079 - New reagents on the horizon for immune tolerance.
2016569 - Macrophage colony-stimulating factor is required for human monocyte survival and acts a...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2009-08-07
Journal Detail:
Title:  Atherosclerosis     Volume:  208     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-01     Completed Date:  2010-04-15     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  335-41     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Chloromethyl Ketones / pharmacology
Animals
Aorta / cytology
Apoptosis*
Biological Transport
Cattle
Cycloheximide / pharmacology
Endothelial Cells / cytology*
Humans
Lipoproteins, LDL / metabolism*
Models, Biological
Permeability
Tight Junctions / metabolism
Tumor Necrosis Factor-alpha / metabolism
Water / chemistry
Grant Support
ID/Acronym/Agency:
HL 57093/HL/NHLBI NIH HHS; R01 HL057093/HL/NHLBI NIH HHS; R01 HL057093-11/HL/NHLBI NIH HHS; R01 HL057093-12/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Amino Acid Chloromethyl Ketones; 0/Lipoproteins, LDL; 0/Tumor Necrosis Factor-alpha; 0/benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 059QF0KO0R/Water; 98600C0908/Cycloheximide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option...
Next Document:  Single nucleotide polymorphism on chromosome 9p21 and endothelial progenitor cells in a general popu...